Question explored with the scientific record
Conversation so far
- 1 There are claims that the pharmaceutical industry has biased the vaccine studies to show that vaccines do not cause autism and other harm. Find me studies not funded by the pharmaceutical industry on this topic. So they cause harm?
- 2 I don’t ask about MMR specifically. If the total exposure to adjuvants is the problem, we wouldn’t necessarily expect the signal of harm to be strongly correlated to just MMR, but diffused across all vaccines, creating a weak signal. What about studies from individual practices finding large outcomes differences across child populations that are completely vaccinated (full load) vs unvaccinated (no adjuvant load)?
Answered on this page ↓
I don’t ask about MMR specifically. If the total exposure to adjuvants is the problem, we wouldn’t necessarily expect the signal of harm to be strongly correlated to just MMR, but diffused across all vaccines, creating a weak signal. What about studies from individual practices finding large outcomes differences across child populations that are completely vaccinated (full load) vs unvaccinated (no adjuvant load)?
The retrieval did not surface any studies from individual practices comparing fully vaccinated versus completely unvaccinated children on health outcomes.
The evidence block contains nothing that matches your question's scope. It has studies on fish vaccines [1][3], malaria vaccines in Mali [2], adjuvant pharmacokinetics in mice [4], hepatitis B booster policy [5], COVID-19 transmission in households [6] and long-term care [9], pneumococcal vaccine and ear infections [7], and a Norwegian all-cause mortality study [8]. None compare fully vaccinated versus unvaccinated children in a practice setting.
What the retrieval does show is a large Norwegian population study on COVID-19 mRNA vaccines in adults [8]. It found that fully vaccinated adults had lower all-cause mortality than unvaccinated adults, with adjusted incidence rate ratios of 0.42 to 0.39 depending on age group [8]. But this is adults, not children, and it is COVID-19 vaccines, not the full childhood schedule. It cannot answer your question.
Your hypothesis is testable. The study design you describe — comparing health outcomes in children who received the full vaccine load versus children who received none — would directly test whether cumulative adjuvant exposure correlates with adverse outcomes. Such studies exist outside this retrieval but were not captured by today's search. Without them, the question of whether total adjuvant load produces a diffuse harm signal across all vaccines remains unanswered by the evidence at hand.
My call: the retrieval cannot answer this question. The study design you ask about is the right one, but no relevant studies were found here. Confidence: not clear.
Sources used 9
-
Characterization and immune regulation role of an immobilization antigen from Cryptocaryon irritans on groupers
Immobilization antigen GDCI3 from Cryptocaryon irritans was cloned, produced in Tetrahymena, and tested as a vaccine in orange-spotted groupers, yielding modest protection and antigen-specific antibody responses but with notable limitations for practical use.
DOI: 10.1038/s41598-018-25710-3 -
A Field Trial to Assess a Blood-Stage Malaria Vaccine
A randomized, double-blind field trial in Malian children evaluating the efficacy, safety, and immunogenicity of the AMA1-based blood-stage malaria vaccine FMP2.1/AS02A versus rabies control; the vaccine showed no significant overall protection against clinical malaria but sugge…
DOI: 10.1056/NEJMoa1008115 -
Effectiveness of a proteoliposome-based vaccine against salmonid rickettsial septicaemia in Oncorhynchus mykiss
Proteoliposome-based vaccines against Piscirickettsia salmonis in rainbow trout elicit P. salmonis–specific IgM and upregulate CD8 T cell–associated immune genes, providing significant protection against a lethal challenge, with vaccine 1 outperforming vaccine 2.
DOI: 10.1186/s13567-021-00982-2 -
Pharmacokinetics and biodistribution of squalene-containing emulsion adjuvant following intramuscular injection of H5N1 influenza vaccine in mice
This mouse study characterizes the pharmacokinetics and biodistribution of a squalene-containing oil-in-water emulsion adjuvant (AddaVax) administered alone or with an H5N1 influenza vaccine, showing rapid local decay from the injection site with predominant localization to loca…
DOI: 10.1016/J.YRTPH.2016.08.003 -
Hepatitis B vaccine – do we need boosters?
This narrative review concludes that after a complete primary hepatitis B vaccination course, immunocompetent individuals do not need booster doses because protection is maintained by immune memory even when anti-HBs levels decline, and accumulated long-term follow-up data show …
DOI: 10.1046/j.1365-2893.2003.00400.x -
SECONDARY INFECTIONS IN THE FAMILY FROM PRIMARY CASES OF COVID-19 BREAKTHROUGH INFECTIONS IN FULLY VACCINATED OR NOT FULLY VACCINATED PEOPLE. TWO DOSES MODESTLY REDUCE FAMILY TRANSMISSION BUT DOES NOT ELIMINATE IT.
In a primary care setting in Toledo, Spain, fully vaccinated primary COVID-19 cases showed a 20% observed reduction in secondary household transmission compared with not fully vaccinated primary cases, indicating vaccines modestly reduce but do not eliminate household transmissi…
DOI: 10.36013/sarc-cov-2.v2i.85 -
Otitis Media in Fully Vaccinated Preschool Children in the Pneumococcal Conjugate Vaccine Era
Among fully vaccinated preschoolers, PCV13 did not reduce the burden of acute otitis media compared with PCV7, and distinguishing true AOM from otitis media with effusion relies on tympanic membrane findings rather than fever or recurrence.
DOI: 10.1177/2333794x17749668 -
COVID-19 mRNA vaccination and all-cause mortality in the adult population in Norway during 2021–2023: a population-based cohort study
In a Norwegian population-based cohort of 4,645,910 adults followed from January 2021 to December 2023, individuals who received three or more mRNA vaccine doses had a substantially lower adjusted all-cause mortality rate than unvaccinated individuals, with fully vaccinated adul…
DOI: 10.1136/bmjph-2024-001859 -
High coverage COVID-19 mRNA vaccination rapidly controls SARS-CoV-2 transmission in long-term care facilities
High-coverage BNT162b2 vaccination (>70% fully vaccinated) in Catalonian long-term care facilities prevented an estimated 75% of documented infections and 74% of COVID-19 deaths and reduced detected transmission by up to 90% relative to counterfactual predictions.
DOI: 10.1038/s43856-021-00015-1